

PATHEON INC  
Form 8-K  
November 04, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 1, 2011**

**PATHEON INC.**

(Exact name of registrant as specified in its charter)

**Canada**  
(State or other jurisdiction

of incorporation)

**000-54283**  
(Commission

File Number)

**Not Applicable**  
(IRS Employer

Identification No.)

**c/o Patheon Pharmaceuticals Services Inc.**

**4721 Emperor Boulevard, Suite 200**

**Durham, NC**  
(Address of principal executive offices)

**Registrant's telephone number, including area code: (919) 226-3200**

**27703**  
(Zip Code)

**Not Applicable**

(Former name or former address, if changed since last report.)

## Edgar Filing: PATHEON INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 1, 2011, Eric W. Evans notified Patheon Inc. (the Company) of his intent to resign, effective as of that date, as the Company's Chief Financial Officer. The Company has commenced a search for a new Chief Financial Officer.

In connection with Mr. Evans's resignation and pursuant to the terms of the employment agreement between Mr. Evans and the Company's indirect wholly owned subsidiary, Patheon Pharmaceuticals Holdings Inc. (the Employment Agreement), Mr. Evans will receive (i) a lump sum payment in cash of \$371,000, his annual base salary, and (ii) a lump sum payment in cash of \$166,950, the average of the bonuses earned by Mr. Evans under the Company's annual incentive plans for the last two fiscal years prior to the effective date of his termination. The Company's obligation to make such payments to Mr. Evans is contingent upon his execution and nonrevocation of a general release, in a form provided by the Company. The Employment Agreement also contains customary non-solicitation and non-competition provisions that extend for 12 months following the effective date of his termination. In addition, the confidentiality undertaking that Mr. Evans executed in connection with the Employment Agreement will remain in effect.

The description of the Employment Agreement contained herein is qualified in its entirety by reference to the Employment Agreement, a copy of which was filed as Exhibit 10.26 to the Company's registration statement on Form 10, filed with the U.S. Securities and Exchange Commission on February 25, 2011.

A copy of the press release announcing Mr. Evans's termination is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

See the Exhibit Index attached hereto.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 1, 2011

**PATHEON INC.**

By: /s/ James C. Mullen  
James C. Mullen  
Chief Executive Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description of Document</b>
99.1	Press release dated November 1, 2011